ProShare Advisors
CTMX icon

ProShare Advisors’s CytomX Therapeutics CTMX Stock Holding History

ProShare Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Buy
+30,448
New +$116K ﹤0.01% 1752
2022
Q2 		– Sell
-18,904
Closed -$51K – 1864
2022
Q1 		$51K Sell
18,904
-4,418
-19% -$17K ﹤0.01% 2112
2021
Q4 		$102K Buy
23,322
+1,090
+5% +$6.38K ﹤0.01% 2203
2021
Q3 		$113K Sell
22,232
-6,276
-22% -$33.6K ﹤0.01% 1899
2021
Q2 		$180K Buy
28,508
+3,100
+12% +$24.1K ﹤0.01% 2173
2021
Q1 		$196K Buy
25,408
+8,270
+48% +$65.5K ﹤0.01% 2050
2020
Q4 		$112K Buy
17,138
+4,157
+32% +$29.7K ﹤0.01% 1975
2020
Q3 		$86K Sell
12,981
-494
-4% -$3.66K ﹤0.01% 1538
2020
Q2 		$112K Buy
+13,475
New +$125K ﹤0.01% 1556
2020
Q1 		– Sell
-15,930
Closed -$132K – 1259
2019
Q4 		$132K Sell
15,930
-1,435
-8% -$9.68K ﹤0.01% 1659
2019
Q3 		$128K Sell
17,365
-575
-3% -$5.67K ﹤0.01% 1519
2019
Q2 		$201K Sell
17,940
-2,223
-11% -$23.3K ﹤0.01% 1438
2019
Q1 		$217K Buy
20,163
+220
+1% +$3.25K ﹤0.01% 1426
2018
Q4 		$301K Sell
19,943
-3,840
-16% -$57K ﹤0.01% 1150
2018
Q3 		$440K Buy
23,783
+2,332
+11% +$53.1K ﹤0.01% 1168
2018
Q2 		$490K Sell
21,451
-21
-0.1% -$536 ﹤0.01% 1131
2018
Q1 		$611K Sell
21,472
-3,534
-14% -$101K ﹤0.01% 1026
2017
Q4 		$528K Buy
+25,006
New +$518K ﹤0.01% 1102

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ProShare Advisors's CTMX Position: Q2 2026 in Review

ProShare Advisors opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 30,448 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #1752 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in CTMX as recently as Q1 2022.

ProShare Advisors first reported a position in CTMX in Q4 2017 and has held it in 18 quarters since. The position peaked at $611K in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • ProShare Advisors held 30,448 shares of CytomX Therapeutics worth $114K as of Q2 2026.
  • CytomX Therapeutics was a new ProShare Advisors position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1752 holding.
  • ProShare Advisors first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 18 quarters since.
  • ProShare Advisors's CytomX Therapeutics position peaked at $611K in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.